Triple-negative breast cancer (TNBC) accounts for approximately 10–20% of all breast cancer cases and is defined by the absence of established hormone receptors, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [1]. Here, ESR1 is linked to triple-negative breast carcinoma.